ABG Analyst expects significant costs increase at Coloplast

ABG Sundal Collier has lowered its recommendation for Coloplast from "hold" to "sell" as it anticipates that the medtech company's costs will increase considerably in the future.

Photo: Coloplast / PR

Coloplast has had its recommendation lowered to "sell" from "hold" by the investment bank ABG Sundal Collier.

The share price target has also been lowered to DKK 900 (USD 140) from DKK 1141 (USD 177).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs